Evidence of hyperglycemia in patients using statin therapy
*Corresponding Author: Hassan Raji Jallab Email: firstname.lastname@example.org Phone: +964 7828943518, Al-Diwaniyah/Iraq/P.O. Box: 88
The use of statin as a primary mode in controlling dyslipidemia became and consequent cardiovascular ischemic events a usual trend in the practice of medicine. Thus, the aim of present Study is to study the association between statin use, in terms of the specific drug used the duration of therapy and dose of treatment, and the development of hyperglycemia and or frank diabetes in a cohort of Iraqi patients on variable statin drugs.
Patients and Methods
The study was designed to be a cross-sectional study involving a cohort of 220 Iraqi patients on statin therapy for controlling dyslipidemia. Patients were selected in a systemic random way from the population of patients already visiting the hospital and the primary health care center. Any patient who was already diagnosed by a specialist to diabetes mellitus before starting statin therapy was excluded from this study. A total of 83 days was the length of the period required to collect data from involved patients. Recent measurements of fasting and random blood sugar were obtained for all patients.
Patients on statin fulfilling criteria for the diagnosis of diabetes, random blood sugar of > 200 mg/dl and/or fasting blood sugar of > 125 mg/dl, accounted for 45 out of 220 patients (20.5%). BMI, duration of statin use and a dose of statin showed a significant association with diabetes mellitus, whereas, none of the other variables had a significant effect on the prevalence rate of diabetes mellitus.
Statin therapy is responsible for at least in part for the development of new-onset type 2 diabetes mellitus or worsening already existing resistance to insulin action.